-+ 0.00%
-+ 0.00%
-+ 0.00%

Lake Street Initiates Coverage On Aytu BioPharma with Buy Rating, Announces Price Target of $8

Benzinga·07/01/2025 14:47:29
Listen to the news
Lake Street analyst Thomas Flaten initiates coverage on Aytu BioPharma (NASDAQ:AYTU) with a Buy rating and announces Price Target of $8.